Preclinical evaluation of a novel and orally active proteasome inhibitor as a therapy in relapsed/refractory multiple myeloma

被引：0
|
作者：
Chauhan, D
Catley, L
Li, G
Hideshima, T
Richardson, P
Palladino, M
Anderson, KC
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Nereus Pharmaceut, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：222S / 222S
页数：1
相关论文
共 50 条
  • [21] DCEP for relapsed or refractory multiple myeloma after therapy with novel agents
    Silvia Park
    Su Jin Lee
    Chul Won Jung
    Jun Ho Jang
    Seok Jin Kim
    Won Seog Kim
    Kihyun Kim
    Annals of Hematology, 2014, 93 : 99 - 105
  • [22] Therapy of relapsed and/or refractory multiple myeloma (RRMM)
    Engelhardt, M.
    Waesch, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 14 - 14
  • [23] Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
    Lonial, Sagar
    Dimopoulos, Meletios
    Palumbo, Antonio
    White, Darrell
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Moreau, Philippe
    Mateos, Maria-Victoria
    Magen, Hila
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Spencer, Andrew
    Oakervee, Heather
    Orlowski, Robert Z.
    Taniwaki, Masafumi
    Roellig, Christoph
    Einsele, Hermann
    Wu, Ka Lung
    Singhal, Anil
    San-Miguel, Jesus
    Matsumoto, Morio
    Katz, Jessica
    Bleickardt, Eric
    Poulart, Valerie
    Anderson, Kenneth C.
    Richardson, Paul
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (07): : 621 - 631
  • [24] Evolution of Therapy for Relapsed/Refractory Multiple Myeloma
    Castillo, Jorge J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (11): : 1433 - 1436
  • [25] Novel Agents for Relapsed and/or Refractory Multiple Myeloma
    Thomas, Sheeba K.
    Richards, Tiffany A.
    Weber, Donna M.
    CANCER JOURNAL, 2009, 15 (06): : 485 - 493
  • [26] Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma
    Tang, Wenjiao
    Li, Yan
    Zhang, Li
    Zhong, Xushu
    Liang, Qiushi
    Zheng, Yuhuan
    Liu, Yuzhang
    Wang, Yafei
    Wang, Xunqiang
    Zeng, Yun
    Fang, Baijun
    Zheng, Li
    Niu, Ting
    CANCER MEDICINE, 2024, 13 (14):
  • [27] Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma
    Holthof, Lisa C.
    van der Horst, Hilma J.
    van Hal-van Veen, Susan E.
    Ruiter, Ruud W. J.
    Li, Fengzhi
    Buijze, Marijke
    Andersen, Morten N.
    Yuan, Huipin
    de Bruijn, Joost
    van de Donk, Niels W. C. J.
    Lokhorst, Henk M.
    Zweegman, Sonja
    Groen, Richard W. J.
    Mutis, Tuna
    HAEMATOLOGICA, 2020, 105 (02) : E80 - E83
  • [28] Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)
    Richardson, Paul G.
    Spencer, Andrew
    Cannel, Paul
    Harrison, Simon J.
    Catley, Laurence
    Underhill, Craig
    Zimmerman, Todd M.
    Hofmeister, Craig C.
    Jakubowiak, Andrzej J.
    Laubach, Jacob P.
    Palladino, Michael A.
    Longenecker, Angie M.
    Lay, Ana
    Wear, Sandra
    Lloyd, G. Kenneth
    Hannah, Alison L.
    Reich, Steve
    Spear, Matthew A.
    Anderson, Kenneth C.
    BLOOD, 2011, 118 (21) : 140 - 141
  • [29] Novel combination therapy for treating proteasome inhibitor-resistant multiple myeloma
    Kim, Byung-Gyu
    Choi, Sung Hee
    Huong Nguyen
    Liang, Fu-Sen
    Kim, Seong-Jin
    Letterio, John
    Huang, Alex
    CANCER RESEARCH, 2024, 84 (06)
  • [30] Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma
    Mark, Tomer M.
    Coleman, Morton
    Niesvizky, Ruben
    LEUKEMIA RESEARCH, 2014, 38 (05) : 517 - 524
12345